Minerva Neurosciences Inc. (NASDAQ:NERV)’s share price traded up 7.3% on Monday . The stock traded as high as $11.91 and last traded at $11.56, with a volume of 699,086 shares trading hands. The stock had previously closed at $10.77.

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Minerva Neurosciences from a “buy” rating to a “sell” rating in a report on Wednesday, June 1st. Jefferies Group reaffirmed a “buy” rating and issued a $17.00 target price on shares of Minerva Neurosciences in a report on Wednesday, June 8th. Finally, JMP Securities raised their target price on Minerva Neurosciences from $10.00 to $17.00 in a report on Thursday, May 26th.

The company has a 50-day moving average price of $10.52 and a 200 day moving average price of $7.21. The company’s market cap is $315.74 million.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Equities analysts anticipate that Minerva Neurosciences Inc. will post ($1.05) earnings per share for the current year.

In other news, Director David Kupfer purchased 55,635 shares of the business’s stock in a transaction on Tuesday, June 21st. The shares were acquired at an average cost of $10.84 per share, with a total value of $603,083.40. Following the completion of the acquisition, the director now owns 209,188 shares of the company’s stock, valued at $2,267,597.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.